Less than a tenth of individuals that would benefit from GLP-1 drugs such as Wegovy can access them, warns the World Health Organization as it releases its first guidance on the medications.
Given in excess of 1,000,000,000 people worldwide currently living with obesity, it is advocating for more widespread and fairer availability to GLP-1 medication.
Per estimates, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.
"The latest guidance acknowledges that excess weight is a long-term condition that can be managed with thorough and lifelong support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are key barriers to widespread availability to the treatments that can aid individuals in losing considerable weight, explains the organization.
Weight-Loss Drug Shortage
Despite the present best projected case, the supply of such drugs might only reach about 100 million people – fewer than 10% of the global need, as stated by the health organization.
The recommendation calls on countries and companies to increase availability, by strategies including licensing agreements.
Exclusive production rights on semaglutide – the main ingredient of a leading brand – is due to expire in multiple countries in 2026.
How Obesity Injections Operate
GLP-1 drugs mimick a biological compound to reduce digestion speed, reduce hunger and enhance satiety so people eat less.
Individuals typically see weight reduction in the initial weeks of commencing the once-weekly jabs.
Research points to users may put most of the weight back on within a year of halting the drug, as their normal appetite return.
To be overweight or obese elevates your chance for developing health problems, such as type 2 diabetes, cardiovascular issues, stroke, and some malignancies.
Excess weight affects people in countries worldwide and was associated with millions of deaths worldwide in 2024, according to the health agency.
